Alpha Cognition Inc
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Alpha Cognition Inc. (Nasdaq: ACOG) is a commercial-stage biopharmaceutical company that develops and commercializes treatments for neurodegenerative diseases, including Alzheimer's disease and cognitive impairment associated with mild traumatic brain injury (mTBI), primarily in the United States and Canada. The company offers ZUNVEYL (benzgalantamine), an FDA-approved oral tablet prodrug of galantamine indicated for mild-to-moderate Alzheimer's disease that features improved gastrointestinal tolerability and reduced side effects such as nausea; its development pipeline includes ZUNVEYL in combination with memantine for moderate-to-severe Alzheimer's disease, ALPHA-1062 sublingual and intranasal formulations targeting acute pancreatitis and mTBI, respectively, and preclinical assets ALPHA-0602 (progranulin), ALPHA-0702, and ALPHA-0802 for neurodegenerative conditions including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy, some of which are available for out-licensing. Founded in 2000 and headquartered at 750 West Pender Street, Suite 1200, Vancouver, British Columbia V6C 2T8, Canada, Alpha Cognition targets long-term care facilities, neurology clinics, and institutional pharmacies serving patients with limited treatment options in these high-unmet-need areas. Recent developments include the commercial launch of ZUNVEYL in March 2025 generating approximately $2.8 million in revenue through the second quarter of commercialization; a $44 million exclusive licensing agreement in January 2025 with China Medical System Holdings for ZUNVEYL development and commercialization in China, with the partner's New Drug Application accepted by Chinese regulators in July 2025; a $35 million oversubscribed public offering priced in September 2025; appointment of Robert Wills to the board of directors in April 2025; positive preclinical data announced in July 2025 for ALPHA-1062 in a military-relevant model of repetitive mTBI; FDA approval of ZUNVEYL in July 2024 following New Drug Application submission in September 2023; expansions of commercial, medical, and leadership teams in early 2025 to support launch activities; and a notice of allowance for a composition-of-matter patent for ZUNVEYL in October 2024.
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's Disease
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's Disease
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's Disease
Alpha Cognition Inc. (ACOG) Q1 2026 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Tops Revenue Estimates
Alpha Cognition Q1 Earnings Call Highlights
Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update
Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026
Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences
Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?
Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425
Alpha Cognition Inc. (ACOG) Q4 2025 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) Reports Q4 Loss, Lags Revenue Estimates
Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update